PGNY Stock Overview
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for PGNY from our risk checks.
Progyny, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$32.50 |
| 52 Week High | US$44.95 |
| 52 Week Low | US$29.44 |
| Beta | 1.48 |
| 1 Month Change | -12.26% |
| 3 Month Change | -13.77% |
| 1 Year Change | -3.01% |
| 3 Year Change | -44.43% |
| 5 Year Change | n/a |
| Change since IPO | 103.89% |
Recent News & Updates
Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?
Apr 03
Progyny: Long-Term Outlook Remains Positive, Reiterate Buy
Mar 15Progyny: Long-Term Thesis Still Intact
Mar 09Recent updates
Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?
Apr 03Progyny: Long-Term Outlook Remains Positive, Reiterate Buy
Mar 15Progyny: Long-Term Thesis Still Intact
Mar 09Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher
Mar 01Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable
Jan 07Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?
Dec 11Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)
Nov 08Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?
Aug 24There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital
Aug 06Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital
May 06When Should You Buy Progyny, Inc. (NASDAQ:PGNY)?
Jan 25Progyny (NASDAQ:PGNY) Shareholders Will Want The ROCE Trajectory To Continue
Dec 12Is It Time To Consider Buying Progyny, Inc. (NASDAQ:PGNY)?
Oct 18Progyny Stock Should Deliver Superior Returns For Investors
Aug 05Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)
Jul 27At US$31.63, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?
Jul 08Progyny: Solving Infertility Problem
Jul 05Progyny Stock: A Hidden Gem Tackling Infertility
May 31Investors Will Want Progyny's (NASDAQ:PGNY) Growth In ROCE To Persist
Apr 18At US$50.90, Is It Time To Put Progyny, Inc. (NASDAQ:PGNY) On Your Watch List?
Mar 31Earnings Not Telling The Story For Progyny, Inc. (NASDAQ:PGNY)
Mar 18Shareholder Returns
| PGNY | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 1.9% | 0.6% | 1.0% |
| 1Y | -3.0% | 2.2% | 21.9% |
Return vs Industry: PGNY underperformed the US Healthcare industry which returned 3.4% over the past year.
Return vs Market: PGNY underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| PGNY volatility | |
|---|---|
| PGNY Average Weekly Movement | 6.4% |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PGNY's share price has been volatile over the past 3 months.
Volatility Over Time: PGNY's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 565 | Pete Anevski | www.progyny.com |
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment.
Progyny, Inc. Fundamentals Summary
| PGNY fundamental statistics | |
|---|---|
| Market cap | US$3.12b |
| Earnings (TTM) | US$62.04m |
| Revenue (TTM) | US$1.09b |
50.4x
P/E Ratio2.9x
P/S RatioIs PGNY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PGNY income statement (TTM) | |
|---|---|
| Revenue | US$1.09b |
| Cost of Revenue | US$849.80m |
| Gross Profit | US$238.80m |
| Other Expenses | US$176.76m |
| Earnings | US$62.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | 0.65 |
| Gross Margin | 21.94% |
| Net Profit Margin | 5.70% |
| Debt/Equity Ratio | 0% |
How did PGNY perform over the long term?
See historical performance and comparison